FTY720 Trial Continues Despite Death, UK

Drug manufacturer Novartis has reported that two people with MS taking the oral drug fingolimod (FTY720) in clinical trials experienced problems with infections, leading to a fatality in one case. The firm said the role of the medicine in the cases was unclear and that the trial will continue. Independent experts recommended that clinical trials with the drug should continue as planned.

More: continued here

Filed under: Clinical Trials on June 10th, 2008